DOCSLIB.ORG

Dextromethorphan/Quinidine for Pseudobulbar Affect

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dextromethorphan/Quinidine for Pseudobulbar Affect Out of the Pipeline Dextromethorphan/quinidine for pseudobulbar affect Alfonso Tan III, MD, and Steven L. Dubovsky, MD The combination of n October 2010, the FDA approved Table dextromethorphan a combination of dextromethorphan Dextromethorphan/quinidine: and quinidine (DM) and quinidine for the treatment I Fast facts reduced the of pseudobulbar affect (PBA)—also called pathological laughing and crying, affective number of daily Brand name: Nuedexta lability, emotional dyscontrol, emotional PBA episodes in 3 Indication: Pseudobulbar affect incontinence, and involuntary emotional Approval date: October 29, 2010 randomized trials expression disorder—in patients with Availability date: First quarter of 2011 neurologic disorders and brain injuries (Ta- Manufacturer: Avanir ble). Despite receiving an approvable letter Dosage forms: Dextromethorphan, 20 mg, in 2006, the compound was not approved plus quinidine, 10 mg at that time because of concerns about the Starting dose: 1 capsule per day arrhythmogenic potential of quinidine, Target dose: 2 capsules per day which prolongs the QT interval. The man- ufacturer conducted another study using one-third of the previous quinidine dose, release of glutamate by injured neurons, which ameliorated this concern and led to disrupting systems for motor control of approval. emotional expression.4,5 PBA is most common in diseases that Clinical implications interfere bilaterally with the corticohypo- PBA is manifested by involuntary labile, thalamic and corticobulbar tracts that con- shallow affect with sudden and unpre- trol voluntary and involuntary faciorespi- dictable laughing, crying, or other emo- ratory mechanisms. However, PBA occurs tional displays that are not appropriate to in unilateral disease as well. The reported the social setting and may not be congru- prevalence of PBA is: ent with the patient’s prevailing mood.1 • 49% in amyotrophic lateral sclerosis Episodes are often paroxysmal and cannot (ALS) be interrupted voluntarily.2 PBA seems to • 18% to 39% in Alzheimer’s disease be caused by a loss of descending cor- • 11% to 34% in stroke tical control of brainstem motor nuclei • 10% to 11% in multiple sclerosis (MS) and possibly the cerebellum, disrupting and traumatic brain injury.6,7 inhibitory mechanisms and resulting in PBA also has been reported in patients inappropriate and involuntary emotional with Parkinson’s disease, brain tumors, display.3 Several studies have demonstrat- Wilson’s disease, syphilitic pseudobulbar ed involvement of subcortical areas, par- ticularly the anterior limb of the internal Dr. Tan is Assistant Professor of Psychiatry, University at Buffalo, Buffalo, NY, and Dr. Dubovsky is Professor and Chair, Department capsule and the bulbar area. The patho- Current Psychiatry of Psychiatry, University at Buffalo, Buffalo, NY, and Adjoint Profes- 60 February 2011 physiology of PBA may involve excessive sor of Psychiatry and Medicine, University of Colorado, Denver, CO. continued on page 65 Out of the Pipeline continued from page 60 palsy, and various encephalitides.1 An es- than those used to treat cardiac arrhyth- timated 880,000 U.S. patients exhibit PBA.8 mias, quinidine inhibits 2D6 and increases Previously, there was no FDA- DM bioavailability.10 DM blood levels in- approved treatment for PBA. However, crease linearly with dose following coad- small controlled trials suggest that selec- ministration with quinidine but are unde- tive serotonin reuptake inhibitors (SSRIs) tectable in most patients given DM alone.7,9 and tricyclic antidepressants (TCAs)— usually in doses lower than those used to Efficacy and tolerability treat depression—may effectively reduce A combination of DM and quinidine (DMQ) symptoms within 2 to 3 days.1 Although reduced Center for Neurologic Study-Labil- dopaminergic agents such as levodopa ity Scale (CNC-LS) scores and the number and amantadine have shown benefit in of daily PBA episodes in 3 randomized tri- open trials, results of controlled studies als.5,7,10 Visit this article at CurrentPsychiatry. using objective measurements have not com for a table summarizing these studies. been positive. An 85-day randomized, double-blind, Clinical Point placebo-controlled study of 150 patients In doses 10 to 25 How it works with PBA associated with MS found that times lower than DM is a serotonergic substance that also DM, 30 mg, plus quinidine, 30 mg, (DMQ is an agonist of 1-sigma receptors and a 30-30) was twice as effective as placebo those used to treat low-affinity, uncompetitive antagonist of within a week in reducing CNC-LS scores.10 cardiac arrhythmias, N-methyl-d-aspartate (NMDA) receptors, DMQ 30-30 patients also had approximate- quinidine inhibits which are important in glutamate signal- ly half as many episodes of inappropriate 2D6 and increases ing, through binding at the phencyclidine laughing, crying, or combined laughing site on the NMDA complex.7,9 The 1-sigma and crying and a 2-fold greater decrease DM bioavailability receptor was thought to be an opioid re- in pain intensity.10 Twenty-one percent of ceptor subtype, but unlike opioid recep- DMQ 30-30 patients experienced complete tors it is not blocked by narcotic antago- remission—no PBA episodes—compared nists and does not have an endogenous with 7% of placebo patients. There were no ligand. However, the 1-sigma receptor significant differences in QT prolongation does modulate activity of opioid mu re- between DMQ 30-30 and placebo. ceptors in addition to altering dopamine A 3-arm, double-blind, 28-day, phase III release and possibly reducing glutamate multicenter trial of 140 ALS patients with release.9 Sigma receptors are densely dis- PBA compared DM monotherapy, quini- tributed in the limbic system and in sys- dine monotherapy, and DMQ 30-30.5 Com- tems related to motor control of affective pared with either drug alone, DMQ 30- expression and seem to be involved in 30 showed greater reduction of CNC-LS learning, responses to stress, mood regula- scores, as well as improved quality of life tion, and drug dependence.1 Because DM and quality of relationships scores, with preferentially binds to brain regions that equal benefit in poor and extensive DM regulate emotional expression,10 it could metabolizers. However, the control condi- normalize glutaminergic neurotransmis- tions may not have been adequate. Quini- sion and other relevant systems in these dine alone would not be expected to have regions.1 However, DM’s exact mechanism an effect on PBA, and the DM dose, which of action is unknown. was the same in combination and mono- Quinidine is a sodium channel antago- therapy, may have been too low to be effec- nist usually used as a type Ia antiarrhyth- tive by itself. In support of this hypothesis, mic.5 DM is subject to extensive first-pass the DM plasma level was 18 times higher metabolism by cytochrome P (CYP) 450 in patients taking DMQ 30-30 than those 2D6 to dextrorphan, which after being taking DM monotherapy. glucuronidated cannot cross the blood- In a manufacturer-sponsored, multi- Current Psychiatry brain barrier. In doses 10 to 25 times lower center, 12-week randomized trial, 326 pa- Vol. 10, No. 2 65 Out of the Pipeline tients with ALS or MS and clinically signif- effects than DM alone because quinidine icant PBA were randomly assigned to DM, increases DM bioavailability and blood lev- 30 mg, plus quinidine, 10 mg (DMQ 30-10), els. The abuse potential of DMQ is not clear. DM, 20 mg, plus quinidine, 10 mg (DMQ Psychosis has been reported with high- 20-10), or placebo, each administered twice er DM doses. The psychotomimetic effects daily.7 Patients with comorbid psychiatric of phencyclidine (PCP) are related to bind- disorders or significant depressive symp- ing to the PCP site on the NMDA receptor toms were excluded. Although daily PBA complex—to which DM also binds—with episodes decreased in all groups, the daily reduced glutamate signaling in informa- rate of PBA episodes was 47% lower for tion processing systems. Therefore, cau- patients taking DMQ 30-10, and 49% lower tion is indicated when prescribing DM to with DMQ 20-10 compared with placebo patients with psychosis. (both P < .001). The mean decrease in the Because DM, a CYP2D6 substrate, is number of daily PBA episodes was 3.9 to combined with quinidine, a 2D6 inhibitor, Clinical Point 4.1 with active treatment and 3.0 with pla- administering DMQ with other 2D6 inhib- Substantial ECG cebo. Side effects were more common with itors could lead to toxicity. When DMQ is changes and adverse active drug than placebo and included diz- combined with SSRIs and similar agents, ziness, nausea, diarrhea, and urinary tract the serotonergic properties of DM could cardiac effects with infection. There were no serious adverse result in serotonin syndrome, which could DMQ have not been cardiac events and no active drug recipi- be fatal if DM is combined with mono- reported ents showed a QTc interval >480 msec or a amine oxidase inhibitors.10 Combinations change from baseline >60 msec.11 Discon- of DM and acetaminophen and antihis- tinuation rates in this study were lower tamines can be dangerous at higher dos- than in studies of DMQ 30-30. In an open- es.10 Because quinidine is metabolized by label extension of 253 patients who com- CYP3A, inhibitors of this enzyme such as pleted the double-blind phase and were ketoconazole, nefazodone, and grapefruit assigned to DMQ 30-10 for 12 weeks, the juice should be avoided. Similarly, inhibi- incidence of treatment-related adverse tion of CYP2D6 by quinidine could raise events was 28%, with a 5.5% rate of serious levels of coadministered 2D6 substrates. adverse events.12 Contraindications. DMQ is contraindi- Safety cated in patients with: Because the 10 mg dose of quinidine in the • heart failure approved formulation of DMQ is 10 times • prolonged QT interval lower than the antiarrhythmic dose, sub- • congenital long QT interval stantial ECG changes and adverse cardiac • history of torsades de pointes effects with DMQ have not been reported.
Load more

Recommended publications
  • Canadian Stroke Best Practice Recommendations
    CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS MOOD, COGNITION AND FATIGUE FOLLOWING STROKE Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression Update 2019 Lanctôt KL, Swartz RH (Writing Group Chairs) on Behalf of the Canadian Stroke Best Practice Recommendations Mood, Cognition and Fatigue following Stroke Writing Group and the Canadian Stroke Best Practice and Quality Advisory Committee, in collaboration with the Canadian Stroke Consortium © 2019 Heart & Stroke Heart and Stroke Foundation Mood, Cognition and Fatigue following Stroke Canadian Stroke Best Practice Recommendations Table 1C Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on selected classes of medications available for use in Canada and more commonly recommended for post-stroke depression. This table should be used as a reference guide by health care professionals when selecting an appropriate agent for individual patients. Patient compliance, patient preference and/or past experience, side effects, and drug interactions should all be taken into consideration during decision-making, in addition to other information provided in this table and available elsewhere regarding these medications. Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin–norepinephrine reuptake Other inhibitors (SNRI) Medication *citalopram – Celexa *duloxetine – Cymbalta methylphenidate – Ritalin (amphetamine)
    [Show full text]
  • From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J
    REVIEW The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J. David Jentsch, Ph.D., and Robert H. Roth, Ph.D. Administration of noncompetitive NMDA/glutamate effects of these drugs are discussed, especially with regard to receptor antagonists, such as phencyclidine (PCP) and differing profiles following single-dose and long-term ketamine, to humans induces a broad range of exposure. The neurochemical effects of NMDA receptor schizophrenic-like symptomatology, findings that have antagonist administration are argued to support a contributed to a hypoglutamatergic hypothesis of neurobiological hypothesis of schizophrenia, which includes schizophrenia. Moreover, a history of experimental pathophysiology within several neurotransmitter systems, investigations of the effects of these drugs in animals manifested in behavioral pathology. Future directions for suggests that NMDA receptor antagonists may model some the application of NMDA receptor antagonist models of behavioral symptoms of schizophrenia in nonhuman schizophrenia to preclinical and pathophysiological research subjects. In this review, the usefulness of PCP are offered. [Neuropsychopharmacology 20:201–225, administration as a potential animal model of schizophrenia 1999] © 1999 American College of is considered. To support the contention that NMDA Neuropsychopharmacology. Published by Elsevier receptor antagonist administration represents a viable Science Inc. model of schizophrenia, the behavioral and neurobiological KEY WORDS: Ketamine; Phencyclidine; Psychotomimetic; widely from the administration of purportedly psychot- Memory; Catecholamine; Schizophrenia; Prefrontal cortex; omimetic drugs (Snyder 1988; Javitt and Zukin 1991; Cognition; Dopamine; Glutamate Jentsch et al. 1998a), to perinatal insults (Lipska et al. Biological psychiatric research has seen the develop- 1993; El-Khodor and Boksa 1997; Moore and Grace ment of many putative animal models of schizophrenia.
    [Show full text]
  • From Sacred Plants to Psychotherapy
    From Sacred Plants to Psychotherapy: The History and Re-Emergence of Psychedelics in Medicine By Dr. Ben Sessa ‘The rejection of any source of evidence is always treason to that ultimate rationalism which urges forward science and philosophy alike’ - Alfred North Whitehead Introduction: What exactly is it that fascinates people about the psychedelic drugs? And how can we best define them? 1. Most psychiatrists will define psychedelics as those drugs that cause an acute confusional state. They bring about profound alterations in consciousness and may induce perceptual distortions as part of an organic psychosis. 2. Another definition for these substances may come from the cross-cultural dimension. In this context psychedelic drugs may be recognised as ceremonial religious tools, used by some non-Western cultures in order to communicate with the spiritual world. 3. For many lay people the psychedelic drugs are little more than illegal and dangerous drugs of abuse – addictive compounds, not to be distinguished from cocaine and heroin, which are only understood to be destructive - the cause of an individual, if not society’s, destruction. 4. But two final definitions for psychedelic drugs – and those that I would like the reader to have considered by the end of this article – is that the class of drugs defined as psychedelic, can be: a) Useful and safe medical treatments. Tools that as adjuncts to psychotherapy can be used to alleviate the symptoms and course of many mental illnesses, and 1 b) Vital research tools with which to better our understanding of the brain and the nature of consciousness. Classifying psychedelic drugs: 1,2 The drugs that are often described as the ‘classical’ psychedelics include LSD-25 (Lysergic Diethylamide), Mescaline (3,4,5- trimethoxyphenylathylamine), Psilocybin (4-hydroxy-N,N-dimethyltryptamine) and DMT (dimethyltryptamine).
    [Show full text]
  • MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: Lmmunocytochemical Evidence for Neurotoxicity
    The Journal of Neuroscience, August 1988, 8(8): 2788-2803 Methylenedioxyamphetamine (MDA) and Methylenedioxymetham- phetamine (MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: lmmunocytochemical Evidence for Neurotoxicity E. O’Hearn,” G. Battaglia, lab E. B. De Souza,’ M. J. Kuhar,’ and M. E. Molliver Departments of Neuroscience, and Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and ‘Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, Baltimore, Maryland 21224 The psychotropic amphetamine derivatives 3,4-methylene- The synthetic amphetamine derivatives 3,4-methylenedioxy- dioxyamphetamine (MDA) and 3,4-methylenedioxymetham- amphetamine (MDA) and 3,4-methylenedioxymethamphet- phetamine (MDMA) have been used for recreational and amine (MDMA) are potent mood-altering drugs that have at- therapeutic purposes in man. In rats, these drugs cause large tained public interest (Seymour, 1986) due to their widespread, reductions in brain levels of serotonin (5HT). This study self-administration by young adults (e.g., Klein, 1985). These employs immunocytochemistry to characterize the neuro- drugs have also been proposed for medical use in psychotherapy toxic effects of these compounds upon monoaminergic neu- because they produce augmentation of mood and enhanced in- rons in the rat brain. Two weeks after systemic administra- sight (Naranjo et al., 1967; Yensen et al., 1976; Di Leo, 198 1; tion of MDA or MDMA (20 mg/kg, s.c., twice daily for 4 d), Greer and Tolbert, 1986; Grinspoon and Bakalar, 1986). How- there is profound loss of serotonergic (5HT) axons through- ever, concern has been raised about the safety of these com- out the forebrain; catecholamine axons are completely pounds based on evidence that they may be toxic to brain seroto- spared.
    [Show full text]
  • The Pharma-Fever That Almost Got Away
    EMERGENCY MEDICINE RESIDENCY CPC The pharma-fever that almost got away XIAO CHI ZHANG, MD, MS; MATTHEW SIKET, MD; WILLIAM BINDER, MD 29 31 EN From the Case Records of the Alpert Medical School of DR. SARAH GAINES: A fever greater than 41.0°C is quite Brown University Residency in Emergency Medicine elevated and unusual. Is this dangerous? What was your differential? DR. XIAO CHI ZHANG: A 68-year-old man was brought into DR. MATTHEW SIKET: Humans generally tolerate tempera- the Emergency Department by his family with chills and tures below 41° C (105.8° F). In contrast to hyperthermia, in altered mental status. Two days prior to his ED presenta- which an imbalance between heat generation versus dissipa- tion, the patient had an episode in which he “spaced-out” tion occurs without up-regulation of the hypothalamic set and was unable to comprehend or acknowledge his wife. She point, fever as a host defense against infection rarely reaches reported that he did not have any signs of seizure activity dangerous levels in neurologically competent individuals. and did not have any focal weakness. The episode lasted Very high temperatures can be related to urosepsis, intraab- approximately 30 minutes and he returned to his baseline. dominal sepsis, C. difficile colitis, meningitis, and central Today he had another episode, but this time associated with venous catheter infections. Hyperpyrexia, defined as tem- chills and rigors. His past medical history was significant perature > 41.5°C (106.7°F) is an uncommon result of infec- for chronic back pain due to bony metastasis from Stage IV tion and usually implies central fever, neurologic malignant non-small cell lung adenocarcinoma, requiring palliative syndrome, malignant hyperthermia, adrenal insufficiency, gamma knife radiation, as well as a daily oral chemotherapy or a drug related cause.1 Our patient was hyperpyrexic, sug- agent, erlotinib, an oral tyrosine kinase inhibitor.
    [Show full text]
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com
    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
    [Show full text]
  • PRESCRIBED DRUGS and NEUROLOGICAL COMPLICATIONS K a Grosset, D G Grosset Iii2
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.045757 on 16 August 2004. Downloaded from PRESCRIBED DRUGS AND NEUROLOGICAL COMPLICATIONS K A Grosset, D G Grosset iii2 J Neurol Neurosurg Psychiatry 2004;75(Suppl III):iii2–iii8. doi: 10.1136/jnnp.2004.045757 treatment history is a fundamental part of the healthcare consultation. Current drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how they are taken A(frequency, timing, missed and extra doses), drugs tried previously and reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunisations may also be of importance. This article examines the particular relevance of medication in patients presenting with neurological symptoms. Drugs and their interactions may contribute in part or fully to the neurological syndrome, and treatment response may assist diagnostically or in future management plans. Knowledge of medicine taking behaviour may clarify clinical presentations such as analgesic overuse causing chronic daily headache, or severe dyskinesia resulting from obsessive use of dopamine replacement treatment. In most cases, iatrogenic symptoms are best managed by withdrawal of the offending drug. Indirect mechanisms whereby drugs could cause neurological problems are beyond the scope of the current article—for example, drugs which raise blood pressure or which worsen glycaemic control and consequently increase the risk of cerebrovascular disease, or immunosupressants
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Catatonia, NMS, and Serotonin Syndrome
    Catatonia, NMS, and Serotonin Syndrome Christopher M. Celano, MD, FACLP Associate Director, Cardiac Psychiatry Research Program, Massachusetts General Hospital Assistant Professor of Psychiatry, Harvard Medical School October 22, 2020 www.mghcme.org Disclosure: Christopher Celano, MD Sunovion Company Pharmaceuticals Employment Management Independent Contractor Consulting Speaking & Teaching I Board, Panel or Committee Membership D – Relationship is considered directly relevant to the presentation I – Relationship is NOT considered directly relevant to the presentation www.mghcme.org Catatonia: How common is it? • 7.8-9.0% prevalence rate – Highest rates in non-psychiatric (i.e., medical) settings and in patients undergoing ECT. • 1.6-5.5% of all patients seen on psychiatry consultation service – Prevalence higher for older patients • Up to 46% of cases may have etiology that is not primarily psychiatric Grover 2015, Carroll 1994, Jaimes-Albornoz 2013, Fricchione 2008 www.mghcme.org When are you called? • Staff reports the patient is “Playing POSSUM” • Perseveration (speech or behavior) • Oppositionality to all requests • Speech that trails off or is whispereD • Slowed response to questions or commands • Undernourished (reports of decreased PO intake) • Motionless but awake www.mghcme.org Diagnosing Catatonia: DSM-5 DSM-5 requires 3 or more of the following: • Catalepsy • Posturing • Waxy flexibility • Mannerisms • Stupor • Stereotypies • Agitation • Grimacing • Mutism • Echolalia • Negativism • Echopraxia American Psychiatric Association 2013 www.mghcme.org Bush-Francis Rating Scale • Excitement • VerBigeration • Immobility/stupor • Rigidity • ComBativeness • Negativism • Autonomic Abnormality • Waxy flexiBility • Impulsivity • Withdrawal • Mutism • Automatic OBedience • Staring • Mitgehen • Posturing/catalepsy • Gegenhalten • Grimacing • AmBitendency • Echopraxia/echolalia • Grasp Reflex • Stereotypy • Perseveration • Mannerisms Bush 1996 www.mghcme.org Challenges with Diagnosis • Clarifying specific symptoms can be difficult – Rigidity vs.
    [Show full text]
  • Triptan Therapy for Acute Migraine
    Triptan Therapy for Acute Migraine Headache John Farr Rothrock, MD University of Alabama at Birmingham, Birmingham, AL Deborah I. Friedman, MD, MPH University of Texas Southwestern, Dallas, TX The “triptans” are 5HT-1B/1D receptor agonists that were developed to treat acute migraine and acute cluster headache. Sumatriptan, the original triptan preparation, has been in general use since 1993, so there has been considerable experience with triptans over time. There are currently seven oral triptans on the market in the United States: sumatriptan (Imitrex™), naratriptan (Amerge™), zolmitriptan (Zomig™), rizatriptan (Maxalt™), almotriptan (Axert™), frovatriptan (Frova™), and eletriptan (Relpax™); brand names may differ by country. There is also a combination preparation of oral sumatriptan/naproxen (Treximet™). Two triptans (sumatriptan, zolmitriptan) are marketed as nasal sprays, and sumatriptan is available for subcutaneous injection, including a needle-free subcutaneous delivery system (Sumavel™). Sumatriptan suppositories are marketed in Europe but not in North America. Zolmitriptan and rizatriptan are sold in an oral disintegrating tablet or “melt” formulation as well as in tablet form; while the “melt” formulations may be more convenient (no liquid is required to propel them into the stomach), they are absorbed similarly to regular tablets and there is no evidence to suggest that they work faster than the tablet formulations. Some patients with migraine-associated nausea prefer the disintegrating tablets while others cannot tolerate their taste. Although all of the triptans initially were investigated for the treatment of migraine headache of moderate to severe intensity and were superior to placebo in those pivotal trials, they appear to be more consistently effective when used to treat migraine earlier in the attack, when the headache is still mild to moderate.
    [Show full text]
  • Neuroleptic Malignant Syndrome Vs Serotonin Syndrome: Can They Be Distinguished Without an Underlying Etiology?
    Neuroleptic Malignant Syndrome vs Serotonin Syndrome: Can They Be Distinguished Without an Underlying Etiology? Roy R. Reeves, DO, PhD; Mark E. Ladner, MD; and Percy Smith, PA The potentially serious complications for patients with neuroleptic malignant syndrome and serotonin syndrome cannot be underplayed by mental health clinicians, patients, and their families. The authors discuss clinical similarities and diagnostic and treatment approaches to the 2 syndromes. euroleptic malignant syn- of symptoms or whether the patient ployment. He had stopped taking his drome (NMS) and sero- was taking different medications that medication (risperidone 3-mg daily) tonin syndrome (SS) are rare could affect both the serotonin and 3 months earlier, because he was Nbut potentially fatal condi- dopamine systems. experiencing adverse effects (AEs) tions associated with the treatment In clinical practice many patients and shortly thereafter hearing voices. of psychotropic medications. Neu- are treated concurrently with both The clinic psychiatrist started him on roleptic malignant syndrome is be- dopamine receptor antagonists and olanzapine 10-mg daily and sertra- lieved to be caused by a reduction in agents that increase serotonin activity. line 50-mg daily. At a follow-up visit dopaminergic activity secondary to Thus, the distinction of NMS and SS a week later, Mr. A showed an im- drug-induced dopaminergic block- may be problematic if these patients provement of his mood and reported age, whereas SS results from an ex- develop symptoms that could be at- that his hallucinations had decreased cess of central nervous system (CNS) tributed to either disorder. This article significantly. serotonin activity, usually because will discuss the clinical similarities of Several days later, Mr.
    [Show full text]
  • JAMA Neurology Pages 525-636
    In This Issue May 2018 Volume 75, Number 5 JAMA Neurology Pages 525-636 Research Opinion Amyloid and Tau Accumulation in Young Adults With ADAD 548 Viewpoint 531 Preventing Sudden Unexpected Although the medial temporal lobe is typically the first area of neurofibrillary tangle depo- Death in Epilepsy sition in aging populations, it is not clear if this is the case for younger individuals who are O Devinsky and Coauthors predisposed to autosomal dominant Alzheimer disease (ADAD). In a cross-sectional study, Quiroz and coauthors used positron emission tomography imaging to measure amyloid and Clinical Review & Education tau deposition in 24 participants (mean [SD] age, 38.0 [7.4] years) from a large Colombian Review kindred with ADAD. The authors report that amyloid accumulates in the cortex of unim- paired presenilin 1 E280A mutation carriers 10 to 15 years before symptom onset, whereas tau deposits emerge in the medial temporal lobe approximately 6 years before and then spread into the cortex as carriers move closer to clinical onset. These findings suggest that amyloid prompts the spread of tau pathology beyond the medial temporal lobe and that the presence of tau is closely associated with memory decline. Editorial perspective is pro- vided by McDade and Bateman. Editorial 536 Risk of Serotonin Syndrome With Triptans and Antidepressants 566 In 2006, the US Food and Drug Administration issued a warning regarding the potential risk of serotonin syndrome with coprescription of triptan antimigraine drugs and selective sero- 620 Review of the Neurological toninreuptakeinhibitororselectivenorepinephrinereuptakeinhibitorantidepressantsbased Implications of von Hippel–Lindau Disease D Dornbos III and Coauthors on a small number of case reports.
    [Show full text]